Inhibition of cytosolic phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III tubulin by Last, Victoria et al.
Last et al. BMC Neuroscience 2012, 13:106
http://www.biomedcentral.com/1471-2202/13/106RESEARCH ARTICLE Open AccessInhibition of cytosolic Phospholipase A2 prevents
prion peptide-induced neuronal damage and
co-localisation with Beta III Tubulin
Victoria Last1,2*, Alun Williams1,3 and Dirk Werling1Abstract
Background: Activation of phospholipase A2 (PLA2) and the subsequent metabolism of arachidonic acid (AA) to
prostaglandins have been shown to play an important role in neuronal death in neurodegenerative disease. Here
we report the effects of the prion peptide fragment HuPrP106-126 on the PLA2 cascade in primary cortical neurons
and translocation of cPLA2 to neurites.
Results: Exposure of primary cortical neurons to HuPrP106-126 increased the levels of phosphorylated cPLA2 and
caused phosphorylated cPLA2 to relocate from the cell body to the cellular neurite in a PrP-dependent manner, a
previously unreported observation. HuPrP106-126 also induced significant AA release, an indicator of cPLA2
activation; this preceded synapse damage and subsequent cellular death. The novel translocation of p-cPLA2
postulated the potential for exposure to HuPrP106-126 to result in a re-arrangement of the cellular cytoskeleton.
However p-cPLA2 did not colocalise significantly with F-actin, intermediate filaments, or microtubule-associated
proteins. Conversely, p-cPLA2 did significantly colocalise with the cytoskeletal protein beta III tubulin. Pre-treatment
with the PLA2 inhibitor, palmitoyl trifluoromethyl ketone (PACOCF3) reduced cPLA2 activation, AA release and
damage to the neuronal synapse. Furthermore, PACOCF3 reduced expression of p-cPLA2 in neurites and inhibited
colocalisation with beta III tubulin, resulting in protection against PrP-induced cell death.
Conclusions: Collectively, these findings suggest that cPLA2 plays a vital role in the action of HuPrP106-126 and
that the colocalisation of p-cPLA2 with beta III tubulin could be central to the progress of neurodegeneration
caused by prion peptides. Further work is needed to define exactly how PLA2 inhibitors protect neurons from
peptide-induced toxicity and how this relates to intracellular structural changes occurring in neurodegeneration.
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Prion diseases or transmissible spongiform encephalop-
athies (TSEs), are fatal neurodegenerative disorders that
include bovine spongiform encephalopathy (BSE) in cat-
tle and Creutzfeldt-Jakob disease (CJD) in man. A key
event in the pathogenesis of these diseases is the mis-
folding of the normal prion protein (PrPC), to a modi-
fied, pathogenic form, termed PrPSc [1]. PrPSc is the
major, if not only, component of the infectious agent of* Correspondence: v.last@medsch.ucl.ac.uk
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reproduction in any medium, provided the orTSEs and PrPSc itself, or defined fragments of PrPSc, in-
cluding the synthetic peptide HuPrP106-126 have been
demonstrated to be cytotoxic to many different cell
types [2-5]. However the exact pathways by which
HuPrP106-126 toxicity is mediated remain to be fully
elucidated. HuPrP106-126 has the ability to aggregate
in vitro to form oligomeric fibrils that are insoluble, pro-
tease resistant and can aggregate further to form amyl-
oid aggregates [2,6,7]. Effects of HuPrP106-126 on cells
include aggregation of PrPC in neuroblastoma cells [7],
copper uptake inhibition in cerebellar neurons [8], p38
MAPK activation in correlation with cell death in SH-
SY5Y cells [9] and an increase in intracellular Ca2+
coupled with membrane viscosity in leucocytes [10].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ling pathway is implicated in prion disease pathogenesis
[11-13]. PLA2 isoforms have a predominant role in the
central nervous system where they are involved in the
pro-inflammatory response, membrane repair, traffick-
ing, neurotransmitter release and apoptosis [14,15]. The
main role of the mammalian PLA2 enzymes is the pro-
duction of lipid mediators vital to activate signal trans-
duction and inflammatory pathways more specifically
they catalyse the production of free fatty acids from the
sn-2 position in membrane phospholipids via hydrolysis
leaving lysophospholipids as a remainder [16]. PLA2
enzymes can be divided into three main groups: extra-
cellular, secretory PLA2 (sPLA2) enzymes, cytosolic PLA2
(cPLA2) that require smaller amounts (nM) of Ca
2+ for
membrane translocation and calcium-independent PLA2
(iPLA2) [14,15,17,18]. cPLA2 does not require Ca
2+ to be
catalytically active [19], however it does require the pres-
ence of nucleophilic Ser-228. In addition, phosphoryl-
ation by MAPK, ERK, PKC and CamKII at the
conserved residues Ser505, Ser757 or Ser515 can also
increase activity [19-21].
The importance of PLA2 in the pathogenesis of the
neuronal degeneration in prion diseases has been indi-
cated by the use of PLA2 inhibitors that reduced PrP
Sc
formation caspase-3 activity and prostaglandin E2 pro-
duction [11,13,22]. In the present study the effects of the
PrP fragment corresponding to amino acid residues
106–126 of human PrP, HuPrP106-126, on the activation
of cPLA2 and other components of the PLA2 pathway
was investigated. As cPLA2 has been reported to relocate
to the nuclear envelope upon activation by the Ca2+
ionophore A23187 in CHO cell lines [23], the hypothesis
that exposure to HuPrP106-126 leads to changes in
cPLA2 distribution within neurons was assessed. In
addition, a previously untested PLA2 inhibitor, palmitoyl
trifluoromethyl ketone (PACOCF3) was investigated for
its effects on HuPrP106-126-induced cPLA2 activation
and neuronal degeneration. This PLA2 inhibitor pre-
vented translocation of PLA2 and subsequent synapse
degeneration and neuronal death.
In the present study we provide important new
insights into the position of cPLA2 in the mechanism
underlying PrP neurotoxicity and implicate the involve-
ment of the cytoskeleton in prion disease pathogenesis.
Results
Exposure of primary cortical neurons to HuPrP106-126
activates cPLA2 and induces a novel relocation
The human prion protein peptide fragment HuPrP106-
126 was used to investigate the effect of PrP upon PLA2
in primary cortical neurons. It is known that cPLA2 is
promptly activated within 1 hour by agonists including
phorbol 12-myristate 13-acetate (PMA) A23187 andionomycin [24-26], this was confirmed in murine pri-
mary cortical neurons via preliminary experiments (Add-
itional file 1: Figure S1), and therefore neurons were
initially treated for 30 minutes. p-cPLA2 was visualised
by confocal microscopy using an anti-phospho cPLA2
antibody against the serine-505 residue.
In untreated neurons a low basal level of p-cPLA2 la-
belling in the nuclear region could be seen, however ex-
posure to 40 μM HuPrP106-126 resulted in a significant
increase in the intensity of p-cPLA2 labelling (P < 0.001),
indicating amplified levels of the enzyme (Figure 1A). In
addition, p-cPLA2 appeared to relocate from the cell
body to the neurites (Figure 1A), an occurrence not pre-
viously noted in cPLA2 activation. The effect of
HuPrP106-126 on PLA2 activation was amino acid se-
quence specific and dependent on the presence of PrP,
as the intensity and localisation of p-cPLA2 labelling was
not altered in cells exposed to 40 μM scrambled
HuPrP106-126 peptide or in PrP null neurons exposed
to HuPrP106-126 (Figure 1A and B). In contrast known
activators of cPLA2, PMA and A23187, induced p-cPLA2
activation and localisation to the nuclear region in both
cell types (P < 0.05). This is consistent with previous
studies which reported that cPLA2 translocates to the
ER and nuclear membrane upon activation [23].
The effect of HuPrP106-126 on the cPLA2 cascade
was further analysed by measuring the release of arachi-
donic acid (AA). Cleavage and subsequent release of AA
by cPLA2 can be used as a marker for PLA2 activity. Pri-
mary cortical neurons were exposed to 40 μM
HuPrP106-126 or scrambled HuPrP106-126. After 15
and 30 minutes PMA and A23187 induced significant
[3H]-AA release (P < 0.01 and P < 0.001 respectively)
(Figure 2A). In contrast, HuPrP106-126 did not induce
[3H]-AA release above untreated or scrambled control
levels. When incubation was prolonged to 24 hours,
PMA and A23187 again induced a significantly higher
[3H]-AA release compared to controls (P < 0.001), and
at this time HuPrP106-126 also induced a significant
[3H]-AA release (P < 0.001) (Figure 2B). Levels of AA
following exposure to scrambled peptide controls
remained comparable to untreated controls.
PACOCF3 inhibits HuPrP106-126-induced cPLA2 activation
and neuronal damage
To examine the specific involvement of cPLA2 in
HuPrP106-126-induced cellular toxicity cells were pre-
treated with the PLA2 inhibitor PACOCF3, a known
cPLA2 inhibitor [27]. Primary cortical neuron samples
were analysed by Western immunoblotting and levels of
activated and total cPLA2 were measured. After expos-
ure to 40 μM HuPrP106-126 for a period of 1 hour and
24 hours, the relative density of p-cPLA2/cPLA2 was sig-
nificantly higher than in untreated neurons (P < 0.05 and
Figure 1 HuPrP106-126 causes cPLA2 activation and relocation in primary cortical neurons. (A) CD-1 murine primary cortical neurons of
an in vivo age of 7 days were treated for 0 (left panel) or 30 minutes (right panel) with 40 μM HuPrP106-126 or HuPrP106-126 scrambled
peptides, or 1 μM PMA+ 5 μM A23187. The cellular localization of p-cPLA2 was analyzed by immunofluorescence using anti-p-cPLA2 (red)
antibody. In addition actin was visualised in PMA+A23187 samples using phalloidin (green). Nuclei were stained with DAPI. Scale bar: 50 μM.
Intensity of p-cPLA2 labelling was measured and normalised to cell number, shown in accompanying graph. (B) PrP null murine primary cortical
neurons were treated with 40 μM HuPrP106-126, HuPrP106-126 scrambled or 1 μM PMA+ 5 μM A23187. Intensity of p-cPLA2 labelling was
measured and normalised to cell number. Data expressed as mean± S.D. of three experiments. *P < 0.05, ***P < 0.001.
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expression levels of p-cPLA2 in neurons treated with
1 μM PACOCF3 and samples pre-treated with PACOCF3
prior to the addition of peptide for 1 hour were not sig-
nificantly different from control samples. However after
24 hours, cPLA2 activation was reduced markedly in
samples pre-treated with PACOCF3 in comparison to
neurons treated with peptide alone (P < 0.01).
Localisation of p-cPLA2 in the presence of PACOCF3
was subsequently determined (Figure 3B). Incubation
with HuPrP106-126 for 30 minutes resulted in increased
p-cPLA2 labelling in the neurites (P < 0.01) (left panel
middle row) as seen previously. In contrast, neurons
pre-treated with PACOCF3 showed a distinct decrease inlevels of p-cPLA2 to levels and location comparable to
that of untreated controls (left panel, bottom row). The
increase in p-cPLA2 labelling in neurons exposed to
HuPrP106-126 compared to untreated neurons was still
apparent after 1 hour (P < 0.01) and 24 hours (P < 0.05)
(middle and right panel). In agreement with Western
immunoblot data, cells pre-treated with PACOCF3
showed reduced levels of cPLA2 phosphorylation in
comparison to those induced by HuPrP106-126 at all
time points measured (P < 0.001, P < 0.01).
The effect of PACOCF3 on [
3H]-AA release was
examined to determine if it would prevent cPLA2 from
accessing its substrate and inhibit HuPrP106-126-
induced activation of cPLA2. Cells exposed to PACOCF3
Figure 2 HuPrP106-126 induces [3 H]-AA release after 24 hours in primary cortical neurons. (A) Primary cortical neurons were incubated
with 1 μCi ml-1 [3 H]-AA for 24 hours. Cells were washed twice with media and treated with 1 μM PMA+ 5 μM A23187, 40 μM HuPrP106-126 or
HuPrP106-126scram for 0, 15 or 30 minutes. Levels of [3 H]-AA were measured in cell lysates and supernatant to calculate a% [3 H]-AA release. (B)
Experiment was repeated with cells treated for 24 hours. Data expressed as mean± S.D. of duplicate samples from three experiments (n = 6).
**P < 0.01, ***P < 0.001.
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trols (Figure 4A). Again primary cortical neurons
exposed to 40 μM HuPrP106-126 for 24 hours released
a significant (P < 0.001) amount of [3H]-AA as seen pre-
viously in Figure 2B. However, when neurons were pre-
treated with PACOCF3 and then exposed to PrP peptide
for 24 hours, only 35% of total [3 H]-AA was released
(Figure 4A). Interestingly, PACOCF3 pre-treatment did
not affect [3H]-AA release induced by PMA or A23187.
To assess the extent of the role of cPLA2 in PrP
peptide action the effect of PACOCF3 on HuPrP106-
126-induced cell toxicity was also analysed. The tox-
icity of HuPrP106-126 was measured via MTT assay
and confirmed that HuPrP106-126 was lethal to pri-
mary cortical neurons, but only after a period of
around 5 days (Figure 4B). This was comparable to
other studies using cortical neurons [28]. Concentra-
tions of 10 μM and 20 μM HuPrP106-126 did not
significantly affect cell survival but 40 μM HuPrP106-
126 caused a 70% decrease in neuronal survival
(P < 0.001). HuPrP106-126 scrambled peptide had no
effect on cell viability. Pre-treatment with PACOCF3,
was protective cells pre-treated with 1 μM or 10 μM
PACOCF3 prior to HuPrP106-126 treatment decreased
the amount of cell death to a 16% and 15% loss re-
spectively (Figure 4C).Further investigation of the neurodegenerative effects
of HuPrP106-126 was investigated by staining neurones
for the synapse-related protein synaptophysin. Synapse
loss is one of the signs of pathology seen in prion infec-
tion [29,30] and Alzheimer’s disease [31]. Synaptophysin
can therefore be used as a neurodegenerative marker for
these disorders. Cortical neurons exposed to HuPrP106-
126 for 30 minutes and then examined by confocal mi-
croscopy showed no significant changes in levels of
synaptophysin (Figure 5A left panel). However, longer
incubations of neurones with HuPrP106-126 peptide
resulted in a significant loss of synaptophysin labelling at
1 and 24 hours (P < 0.05) (Figure 5A middle and right
panel). PACOCF3, in addition to inhibiting HuPrP106-
126-induced cPLA2 activation and AA-release, also
protected against synapse damage with synaptophysin
levels in neurons pre-treated with PACOCF3 prior to
peptide treatment being equivalent to untreated controls
(Figure 5 bottom row).
p-cPLA2 co-localises with beta III tubulin in neurons
exposed to HuPrP106-126
As the translocation of p-cPLA2 within neuronal neur-
ites in the presence of HuPrP106-126 had not been pre-
viously reported the question whether HuPrP106-126
treatment leads to a potential re-arrangement of the
Figure 3 PACOCF3 prevents HuPrP106-126-induced cPLA2 activation. (A) Primary cortical neurons were treated with 40 μM HuPrP106-126
for 1 hour or 24 hours, or pre-treated with 1 μM PACOCF3 before the addition of peptide. Samples were analysed by immunoblotting and the
amount of p-cPLA2 and total PLA2 was calculated by densitometry. (B) Neurons were further analysed by confocal microscopy. Samples were
treated with HuPrP106-126 for 30 minutes, 1 hour or 24 hours, or pre-treated with PACOCF3 prior to HuPrP106-126. p-cPLA2 was labelled (red)
and nuclei were stained with DAPI. Fluorescence intensity of p-cPLA2 was measured and normalised to cell number, shown in the accompanying
graph. Data expressed as mean± S.D. of three experiments *P < 0.05, **P < 0.01, ***P < 0.001.
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investigated. To examine the process by which
HuPrP106-126 induced p-cPLA2 translocation, neurons
were labelled with a range of cytoskeletal markers, in-
cluding actin, vimentin and beta III tubulin. p-cPLA2 did
not colocalise with actin or vimentin prior to or after
treatment with HuPrP106-126 (data not shown). How-
ever, 4.8% of p-cPLA2 colocalised with beta III tubulinbefore peptide treatment, and this increased to 54%
(P < 0.001) after 30 minutes exposure to HuPrP106-126
(Figure 6A and B). Colocalisation was predominantly in
the neurites of the cells. Cells pre-treated with
PACOCF3 before exposure to peptide had low levels of
cPLA2 phosphorylation and the average colocalisation of
p-cPLA2 with beta III tubulin was 8%. In addition, colo-
calisation appeared to be in the nuclear region rather
Figure 4 PACOCF3 decreases HuPrP106-126-induced [
3 H]-AA
release and cell death in primary cortical neurons. (A) Primary
cortical neurons were labelled with [3 H]-AA for 24 hours, and
subsequently pre-treated for 3 hours with 1 μM PACOCF3 before
adding peptides or 1 μM PMA+ 5 μM A23187. Cells were lysed after
24 hours and levels of [3 H]-AA measured in supernatant and lysates
to calculate a% [3 H]-AA release, ***P < 0.001. (B) Primary cortical
neurons were incubated with HuPrP106-126 at varying
concentrations for 24 hours (grey bars) or 5 days (black bars). Cell
viability was measured using the MTT assay. Data expressed as
mean± S.D. of three observations taken from three experiments
(n = 9), ***P < 0.001. (C) Primary cortical neurons were pre-treated for
3 hours with 1 μM PACOCF3 and subsequently exposed to 40 μM
HuPrP106-126 for a further 5 days. Cell viability was measured using
MTT. Data expressed as mean± S.D. of three observations from three
experiments (n = 9), ***P < 0.001.
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and beta III tubulin also appeared to be PrP-specific.
6.3% colocalisation was measured between p-cPLA2 and
beta III tubulin after exposure to a non-toxic scrambled
HuPrP106-126 peptide control (Figure 6) and 6.9% colo-
calisation was noted in PrP null neurons treated with
HuPrP106-126 (Figure 7) both comparable to untreatedcontrol levels. Interestingly p-cPLA2 labelling in PrP null
neurons was localised to the nucleus after HuPrP106-
126 exposure, indicating that PrP could define the local-
isation of p-cPLA2 within the cell.
Discussion
It has previously been shown that PLA2 could play a key
role in the neurodegenerative processes in prion disease
pathogenesis [11-13]. The aim of the present study was
to examine the effects of neurotoxic PrP peptide on
cPLA2 activation and location in murine primary cortical
neurons. Exposure of primary cortical neurons to
HuPrP106-126 significantly increased levels of p-cPLA2
with subsequent release of AA prior to synapse loss and
subsequent cell death. It was also shown that cPLA2
translocated to a novel region of the neuron in a PrP-
dependent manner when stimulated by HuPrP106-126
this was not seen when stimulated by other PLA2 ago-
nists PMA and A21387 suggesting that this abnormal
translocation was PrP-disease related. The effects of
HuPrP106-126 were prevented by an inhibitor of cPLA2.
The regulation of cPLA2 is complex and involves a
variety of cellular processes including phosphorylation of
serine residues and an increase in intracellular calcium
to induce membrane translocation [20,23]. It is not clear
how cPLA2 translocates although shuttle proteins and
attraction to lipids or proteins within the membranes
have been suggested [33].
Here confocal microscopy showed an increase in p-
cPLA2 after 30 minutes incubation with HuPrP106-126
but without apparent translocation to the ER or nuclear
membrane as described in previous reports [34,35] and
as found using PMA and A23187 in this study. One ex-
planation for this could be that PrP peptides may be
interacting with intracellular PrP rather than glycosyl-
phosphatidylinositol (GPI)-linked PrP at the cell surface
and this may promote p-cPLA2 to localise in neurites.
PrPC is usually anchored to the cell membrane via a GPI
anchor [36], however transmembrane forms of PrP,
CtmPrP and NtmPrP exist that are localised to the endo-
plasmic reticulum membrane [37]. Indeed, the peptides
used in this study contain part of the transmembrane
CtmPrP region [38]. Alternatively, the HuPrP106-126
may interact with PrPC to cause clustering of PrP-GPIs
[39] and create altered intracellular signalling resulting
in p-cPLA2 locating to neurites.
In this study colocalisation of p-cPLA2 and beta III
tubulin after exposure to HuPrP(106–126) was demon-
strated. As HuPrP106-126 has been shown to bind dir-
ectly to tubulin [40], the data presented here potentially
indicate a direct interaction of HuPrP106-126 and p-
cPLA2 involved beta III tubulin filaments. In line with
that observation, PrPC has been shown to associate with
tubulin in porcine and Syrian hamster brain extracts
Figure 5 PACOCF3 inhibits the decrease in synaptophysin expression caused by HuPrP106-126 treatment. (A) Primary cortical neurons
were either left untreated, or treated with 40 μM HuPrP106-126 for 30 minutes, 1 hour or 24 hours. Some samples were pre-treated with 1 μM
PACOCF3 before addition of peptide. The cellular localization of synaptophysin was analyzed by immunofluorescence using anti-synaptophysin
(green) antibody. The nuclei were stained with DAPI. Scale bar: 50 μM. (B) Intensity of synaptophysin labelling was measured and normalised to
cell number. Data expressed as mean± S.D. of three experiments, *P < 0.05.
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which concluded that cPLA2 co-immunopreciptated
with actin.
Interaction of PrP peptide and p-cPLA2 with tubulin
could facilitate their transport to neurite and axon term-
inals to mediate the disease-associated synapse degener-
ation as axonal membrane proteins are transported via
microtubules [45]. The interaction of PrP with tubulin
has been related to the active transport of PrP in cells,
by anterograde and retrograde movement via a kinesin/dyenin mechanism in N2a cells [46], in hamster periph-
eral nerves [47] and in the entorhinal cortex of rats [48].
Therefore, any association of cPLA2 with tubulin could
bring it into close association with PrP. Indeed, p-cPLA2
co-immunoprecipitated with PrPSc in ScGT1 cells [49]
and cPLA2 colocalises transiently with the murine PrP
peptide MoPrP(105–132) in untreated neuroblastoma
cells [38]. This supports the hypothesis that there is a
direct interaction of cPLA2 with tubulin in the presence
of HuPrP106-126 and endogenous PrP.
C Any subsequent
Figure 6 p-cPLA2 and beta III tubulin colocalise in neurons after HuPrP106-126 treatment and is inhibited by PACOCF3. (A) Primary
cortical neurons were untreated, treated with 40 μM HuPrP106-126, HuPrP106-126scram, or pre-treated with 1 μM PACOCF3 prior to addition of
peptide. p-cPLA2 and beta III tubulin was analyzed using anti-p-cPLA2 (red) and anti-beta III tubulin (green) antibodies. Nuclei were stained with
DAPI. Images show a representative picture of three individual experiments. Scale bar: 50 μM (B) Colocalisation of the two antibodies was
measured by correlation. An overall average colocalisation of all results is shown. ***P < 0.001.
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Figure 7 p-cPLA2 and beta III tubulin do not colocalise in PrP null neurons treated with HuPrP106-126. (A) Primary cortical neurons from
PrP null mice were left untreated, or treated with 1 μM PMA+ 5 μM A23187, or 40 μM HuPrP106-126 for 30 minutes. Images show a
representative picture of two individual experiments. Scale bar: 50 μM. (B) Colocalisation of the two antibodies was measured by correlation. An
overall average colocalisation of all results is shown. *P < 0.05.
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of apoptosis [50].
The present study also supports previous reports that
activation of cPLA2 is associated with PrP peptide-
induced neurotoxicity [51]. Indeed the PLA2 inhibitor
PACOCF3 inhibited cPLA2 phosphorylation in primary
cortical neurons even after 24 hours of HuPrP106-126
exposure. Furthermore, only low levels of p-cPLA2 were
seen by confocal microscopy and colocalisation with
beta III tubulin was lost. This correlated with prevention
of [3H]-AA release and ultimately cells were protectedagainst synaptic synaptophysin loss and neuronal death.
This is consistent with published data where levels of
synaptophysin have been found to decrease in brains of
CJD patients [52] and murine scrapie models [53]. The
finding that PACOCF3 did not appear to affect [
3H]-AA
release induced by PMA and A23187 are consistent with
a report that PMA induced activation of cPLA2 may not
involve the Ser505 phosphorylation site therefore the
mechanism of PACOCF3 may not effect PMA and
A23187-induced cPLA2 phosphorylation [54]. Alterna-
tively the agonist A23187 has been shown to have
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fatty acid release, therefore the lack of effect of
PACOCF3 on [
3H]-AA release induced by PMA and
A23187 could be due to a high amount of unlabelled
material in the culture medium [55]. PACOCF3 pre-
treatment inhibited the loss of synaptophysin, indicating
that PLA2 could be implicated in synapse degeneration
and loss of synaptophysin. It also suggests that PLA2
changes occur as an early event prior to neuronal death,
again consistent with in vivo data [11,56] in which pros-
taglandin E2, an end-product of the PLA2 pathway was
elevated in specific brain regions before the onset of de-
tectable neuronal loss. Activated microglia also precedes
neuronal loss and is a pathological hallmark of prion dis-
ease [56]. The neurotoxicity of PrP peptides are greatly
enhanced in the presence of microglia [3], however
microglial cell contamination of neuronal cultures as
measured by GFAP labelling was negligible in this study
therefore this is unlikely to have affected results.
The implication that PLA2 changes are a preliminary
occurrence prior to cell death is also compounded by
the toxicity data seen in this study cortical neurons show
a significant decrease in metabolic activity after 5 days
whereas an increase in p-cPLA2 is seen after 30 minutes.
It is likely that the increase in cPLA2 phosphorylation
encourage the cell into a cascade of intracellular signal-
ling events which eventually lead to cell death. This is
the first report of PACOCF3 protecting neurons against
PrP-induced toxicity however the PACOCF3 analogue
arachidonyl trifluoromethyl ketone (AACOCF3) has pre-
viously been reported to reduce PrPSc levels in neuro-
blastoma cells [13]. The results presented here are also
consistent with earlier data showing an increased sur-
vival of SHSY-5Y cells treated with the PACOCF3
analogue AACOCF3 before exposure to HuPrP106-126
[22].
Thus cPLA2 inhibition by AACOCF3 and PACOCF3
indicates a vital role for cPLA2 activation in neuronal
death, and indicates a potential role for the use of cPLA2
inhibitors for neuroprotection in neurodegenerative
diseases. PACOCF3 and AACOCF3 are both trifloro-
methyl ketone analogues of fatty acids [57]; AACOCF3
inhibits cPLA2 by binding to its active site [58] and it
is likely that its analogue PACOCF3 acts in a similar
way. As PLA2-induced AA release causes free oxygen
radical release membrane disruption [14] and subse-
quent cellular damage, the neuroprotective action of
PACOCF3 and other PLA2 inhibitors could be through
inhibition of these events, and/or through disrupting
colocalisation of PrPSc, p-cPLA2 and beta III tubulin, by
attaching to the active site of cPLA2. Whether cPLA2
is activated via direct cell exposure to neurodegenera-
tive peptides or is due to a secondary event remains to
be investigated.Conclusions
We provide evidence that neurotoxicity resulting from
exposure to prion peptide HuPrP106-126 is dependent
on cPLA2 phosphorylation and a novel translocation to
neurites coupled with an interaction with beta III tubu-
lin. Inhibition of cPLA2 activation provides protection to
neurons from PrP peptide induced synapse damage and
cell death. Taken together these findings suggest a vital
role for cPLA2 in the progress of neurodegeneration
caused by prion peptides.
Methods
Reagents and antibodies
PMA A23187, poly-D-lysine, paraformaldehyde, Tris–
HCl, SDS, glycerol, Na3VO4 and palmitoyl trifluoro-
methyl ketone (PACOCF3) were obtained from Sigma
(Dorset, UK). Primary antibodies included mouse mono-
clonal cPLA2 (4-4B-3C, sc-454), rabbit polyclonal anti-
phosphorylated cPLA2 (Ser505 residue, sc-34391), goat
polyclonal anti-synaptophysin (sc-7568) (Santa Cruz Bio-
technology, Santa Cruz, CA) and goat polyclonal beta III
tubulin (Abcam, Cambridge). Fluorescently conjugated
secondary antibodies included anti-rabbit Alexa
Fluor555 and anti-goat Alexa Fluor 488 (Invitrogen,
Paisley, UK).
Isolation of primary cortical neurons
Primary cortical neurons were prepared from day 15.5
gestation CD-1 mice (Charles River Margate, UK), or
129/Ola PrP null mice originally obtained from Jean
Manson as previously described [59]. Primary cortical
neurons were prepared from the brains of mouse
embryos as described previously [60] and seeded into
24-well or 96-well trays and maintained in neurobasal
media (NBM) with B27 components (Invitrogen, Paisley,
UK), for 7 days prior to use.
Peptide-induced cell death assays
Primary cortical neurons were seeded at a density of
1x106 cells per ml in NBM and left in culture for 7 days.
Cells were subsequently treated for 5 days with 10 μM –
40 μM HuPrP106-126 or HuPrP106-126 scrambled
(Bachem St. Helens, UK). To ensure homogenous distri-
bution in solution, peptides were sonicated 3 x 10 sec-
onds prior to use. In inhibitory experiments, neurons
were pre-treated with 1 μM or 10 μM of the PLA2 in-
hibitor PACOCF3 for 3 hours before the addition of pep-
tide or vehicle control. After incubation, medium was
removed and cell survival was measured by the addition
of 500 μg ml-1 of 3,[4,5 dimethylthiazol-2yl]-2,5 diphe-
nyltetrazolium bromide (MTT) (Sigma) which is reduced
to a formazan dye in metabolically active cells. MTT
was left on the cells for 3 hours with the culture tray
kept at 37°C. Cells were then lysed and the MTT-
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per well of DMSO. Optical density was quantified using
a SpectraMax M2 microplate reader (Molecular Devices,
CA, USA) at a wavelength of 550 nm. Absorbance mea-
sured in MTT assays was expressed as percent of the un-
treated controls (defined as 100%).
Measurement of [3 H]-arachidonic acid release
Primary cortical neurons were seeded at 2 x 105 cells per
well in 24-well trays and left in culture for 7 days. Cells
were then incubated for 24 hours with 1 μCi per ml
(specific activity 212 Ci per mmol) [5,6,8,9,11,12,14,
15-3H]AA (Amersham Biosciences Amersham, UK) in
NBM. Cells were washed twice in NBM and new media
containing 0.3% fatty acid free BSA (PAA, Somerset,
UK) and 40 μM HuPrP106-126 or scrambled peptide
was added. Positive controls included a PKC activator,
phorbol 12-myristate 13-acetate (PMA) used at 1 μM,
with 5 μM of the calcium ionophore, A23187. In some
experiments 1 μM PACOCF3 was added in media for
3 hours before the addition of peptides. Supernatants
were taken after 0, 15 or 30 minutes or 24 hours and
centrifuged for 5 min at 16000 x g. Cells were lysed in
lysis buffer (63.5 mM Tris–HCl (pH 6.8), 10% (v/v) gly-
cerol, 2% (w/v) SDS, 1 mM Na3VO4, HALT protease in-
hibitor cocktail (Pierce, Northumberland, UK). Samples
were added to 4 ml scintillant and radioactivity was
determined by β-scintillation counting (Packard Tri
Carb Liquid Scintillation Analyser, Counter B 1990).
Confocal microscopy
Murine cortical neurons were seeded onto poly-D-lysine
coated coverslips at 2 x 105 cells per coverslip and left in
culture for 7 days. Cells were treated with 40 μM
HuPrP106-126 or a scrambled peptide control. In some
experiments 1 μM PACOCF3 was added in NBM for
3 hours before the addition of peptides. The media was
removed and cells washed in PBS before being fixed with
4% paraformaldehyde (PFA) pH 7.4 for 15 min at room
temperature. Cells were subsequently permeabilised in
0.1% (v/v) Triton-X100 (Sigma Dorset, UK) in PBS for
10 min at room temperature. Cells were washed, and
then incubated with 1% (v/v) donkey or rabbit serum
(Chemicon) in PBS for 1 hour at room temperature to
block. Cells were then exposed to primary antibody in
diluent (1% donkey or rabbit serum) in PBS overnight at
4°C. The coverslips were then washed and counter-
stained with the appropriate AlexaFluor secondary anti-
body for 1 hour. Coverslips were washed again,
incubated with phalloidin (5 U per ml) for 20 min and
exposed to 4 μg per ml DAPI in PBS for 10 min at room
temperature to label nuclei. Cells were given a final rinse
with ultrapure water before being mounted onto Super-
frost Plus slides using Vectashield (Vector Labs,Peterborough, UK) and sealed with Eukitt (Agar Scien-
tific, Stansted, UK). Fluorescence was visualised using a
Leica SP5 RS confocal microscope (Leica Microsystems,
Milton Keynes, UK) with HC PL Fluotar 20x 0.5 dry
objective.
Western blotting
Primary cortical neurons were seeded at 5 x 105 cells per
well in 24 well-plates and left in culture for 7 days re-
spectively. NBM was removed and replaced with media
containing 40 μM HuPrP106-126. Some cells were pre-
treated with 1 μM PACOCF3 prior to addition of pep-
tide. After removal of supernatant cells were washed
with ice-cold PBS and 0.4 mM sodium orthovanadate
(Na3VO4) (Sigma). Cells were lysed in 100 μl of ice-cold
lysis buffer (63.5 mM Tris–HCl (pH 6.8), 10% (v/v) gly-
cerol, 2% (w/v) SDS, 1 mM Na3VO4, HALT protease in-
hibitor cocktail (Pierce, Northumberland)). 20 μg per
lane of protein was resolved using a graduated 4-12%
Novex Tris-glycine gel (Invitrogen) using the XCell
Surelock Mini-Cell apparatus (Invitrogen). Gels were
run at 125 V for around 1.5 hours (Bio-Rad, Hemel
Hempstead, UK). Proteins were transferred onto nitro-
cellulose membrane (Amersham Biosciences, Bucking-
hamshire, UK) at 25 V for 60 min and then blocked for
two hours at room temperature in PBS containing 5%
milk powder (w/v) and 0.1% (v/v) Tween 20 (PBST)
(Sigma). Membranes were incubated overnight at 4°C in
PBST with 5% (w/v) milk powder containing anti-cPLA2
mAb (1:1000), phosphospecific anti-cPLA2 polyclonal
(p-cPLA2) (1:1000), (Santa Cruz Biotechnology, Santa
Cruz, CA) and anti-β-Actin mAb (1:5000) (Chemicon,
Hampshire, UK). Blots were washed in PBST (1 x
15 min, 3 x 5 min) and incubated with goat anti-mouse
or rabbit IgG horseradish peroxidase-conjugated anti-
body (1:2000) (Pierce) for two hours at room
temperature. After washing, an enhanced chemilumines-
cence kit (Amersham Biosciences) was used to detect
bound antibody. Blots were analysed using ImageJ soft-
ware (Rasband, W.S., ImageJ, U. S. National Institutes of
Health, Bethesda, Maryland, USA, http://rsb.info.nih.
gov/ij/, 1997–2007).
Statistical analysis
Results from at least three independent experiments are
expressed as mean ± standard deviation (S.D.) unless sta-
ted otherwise. Colocalisation of molecules in confocal
microscopy was calculated using Pearson’s correlation
coefficient using Leica LAS AF software (Leica, Milton
Keynes, UK). The intensity of the fluorescent label of
interest was measured using ImageJ software (version
1.41, Maryland, USA). The overall intensity was divided
by the number of cells counted in replicate experiments
to give an average intensity for all images. Statistical
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dent’s t-test or one-way analysis of variance (ANOVA)
with a Bonferroni post hoc test using SPSS software (ver-
sion 14.0, Chicago, USA), with significance set at
P < 0.05.
Additional file
Additional file 1: Figure S1 PMA and A23187 induce cPLA2
activation and subsequent release of arachidonic acid within
30 minutes. Primary cortical neurons were labelled with [3 H]-AA for
24 hours then treated with 1 μM PMA and 5 μM A23187 for 30 minutes.
Cells were lysed and levels of [3 H]-AA measured in supernatant and
lysates to calculate a% [3 H]-AA release. Data expressed as mean± S.D. of
three experiments. **P < 0.01, ***P < 0.001.
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